Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder

Wright, Christopher; Mellon, K.; Johnston, Patricia A.; Lane, David P.; Harris, Adrian L.; Horne, C. H. W.; Neal, David E.

doi:10.1038/bjc.1991.211

Cited by 179 publications

(92 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Genes involved in cell cycle control and affected in urothelial carcinoma comprise MTSJ/p16 and MTS2/p15 encoding inhibitors of cyclin-dependent kinases (CDKs) (Orlow et al, 1995), cyclin Dl (Bringuier et al, 1994), RB (Xu et al, 1993) and MYC (Lipponen, 1995;Schmitz-Drager et al, 1996). In addition, depending on stage and grade, a considerable fraction of urothelial carcinomas display accumulation of p53 protein usually due to point mutations in the gene (Wright et al, 1991;Cordon-Cardo et al, 1994;Esrig et al, 1994;Schmitz-Drager et al, 1994;Williamson et al, 1994;Uchida et al, 1995;Vet et al, 1995).…”

mentioning

confidence: 99%

Frequent and heterogenous expression of cyclin-dependent kinase inhibitor WAF1/p21 protein and mRNA in urothelial carcinoma

Clasen

Schulz²,

Gerharz³

et al. 1998

Br J Cancer

View full text Add to dashboard Cite

No mutations were observed in the WAF1/p21 gene in these tumours, but two were heterozygous for the codon 31 polymorphism. These data indicate that p21 is frequently expressed in superficial, well differentiated urothelial carcinomas, but less often in muscle-invasive urothelial carcinomas, irrespective of their p53 status. The expression of p21 and its prevalence in low-stage tumours may reflect residual growth-regulatory influences potentially impeding but not necessarily inhibiting tumour development.

show abstract

mentioning

confidence: 99%

Frequent and heterogenous expression of cyclin-dependent kinase inhibitor WAF1/p21 protein and mRNA in urothelial carcinoma

Clasen

Schulz²,

Gerharz³

et al. 1998

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…The Ki-67 antigen recognized by the MIB-1 monoclonal antibody is a useful proliferation marker (7)(8)(9)(10). Overexpression of the p53 gene product has been reported to be a marker of progression in urothelial carcinoma (11)(12)(13)(14). CK20 is the last known component on the cytokeratin subgroup of intermediate filaments (15).…”

mentioning

confidence: 99%

Immunohistochemical Expression of CK20, p53, and Ki-67 as Objective Markers of Urothelial Dysplasia

et al. 2003

View full text Add to dashboard Cite

Urothelial dysplasia and carcinoma in situ (CIS) are related to recurrence and progression of urothelial carcinoma. Distinguishing CIS and dysplasia from reactive atypia is often difficult on the basis of histological features alone. Cytokeratin 20 (CK20), p53, and Ki-67 are related either to neoplastic change or prognosis in urothelial proliferations. The objective of the present study was to establish the immunohistochemical pattern of these three antibodies in urothelial dysplasia and CIS. Three groups of patients were evaluated: 40 nonneoplastic urothelial samples, 50 cases with histologically incontrovertible CIS, and 30 samples with nonconclusive atypical changes (atypia of unknown significance). Monoclonal antibodies (MoAb) against CK20, p53, and Ki-67 (MIB-1) were used on paraffin-embedded samples. Nonneoplastic urothelium showed no reactivity to CK20 except for umbrella cells; p53 and Ki-67 were negative or weakly positive in <10% of basal cells. In the CIS group, 42% showed positivity for all three MoAb; 44%, for two; and 14%, only for one. CK20 was positive through the full thickness of the urothelium in 72% of cases, p53 was positive in 80% of cases, and Ki-67, in 94% of cases. In the third group, the suspected dysplastic cells showed strong positivity in scattered cells through the epithelium in 75% of cases. Aberrant CK20 expression in urothelial cells plus overexpression of p53 and Ki-67 are indicators of dysplastic change in urothelial mucosa. Thus, immunohistochemistry is a useful tool to confirm the diagnosis of CIS and could be helpful to distinguish dysplastic changes from reactive atypia.

show abstract

“…EGFR overexpression has been documented in gastric, esophageal, pancreatic, nonsmall cell lung, prostate, squamous cell, breast, ovarian, cervical, glioma, and bladder cancers. 2,[15][16][17][18][19][20][21][22][23][24] Elevated tissue EGFR reportedly has prognostic significance in several solid tumors. Tissue EGFR overexpression in patients with squamous cell carcinoma of the head and neck 23,24 and in patients with epithelial ovarian cancer 25 was correlated with a poor prognosis and disease progression.…”

mentioning

confidence: 99%

Serum epidermal growth factor receptor/HER‐2 predicts poor survival in patients with metastatic breast cancer

Souder

Leitzel

Ali

et al. 2006

Cancer

View full text Add to dashboard Cite

BACKGROUND.Epidermal growth factor receptor (EGFR, HER‐1, and erbB1) is overexpressed in primary breast cancer and had been identified as a poor prognostic factor.METHODS.Pretreatment serum EGFR levels were quantified by using an enzyme‐linked immunoadsorbent assay in a Phase III first‐line trial of letrozole and tamoxifen and were correlated with patient outcomes.RESULTS.Serum EGFR levels in a control group of 117 healthy, postmenopausal women measured 64.1 ± 13.3 ng/mL (mean ± standard deviation). Using a cutoff EGFR level of 44.1 ng/mL from the control group (5% nonparametric method), 53 of 535 patients (10%) had decreased serum levels of EGFR. Patients with decreased serum EGFR had no significant difference in objective response rate (ORR), clinical benefit rate (CBR), time to progression (TTP), or time to treatment failure (TTF); however, they did have significantly reduced survival compared with patients who had normal serum EGFR levels (median survival, 23.3 months vs. 30.9 months; P = .007). A combined analysis of pretreatment serum EGFR and HER‐2 yielded no additional predictive information for ORR, CBR, TTP, or TTF compared to serum HER‐2 alone. However, in the current analysis, a subgroup of patients who had decreased serum EGFR and normal serum HER‐2 was identified (n = 39 of 535 patients; 7.3%) that had significantly reduced survival compared with patients who had normal serum levels of both EGFR and HER‐2 (median survival, 23.5 months vs. 37.1 months; P = .005). In multivariate analysis, a decreased serum EGFR level remained a significant independent prognostic factor for decreased survival (hazards ratio, 1.58; P = .007).CONCLUSIONS.In patients who had metastatic breast cancer, decreased serum EGFR/normal serum HER‐2 predicted shorter survival compared with patients who had normal levels of serum EGFR/HER‐2. This patient subgroup deserves further study to assess their response to and selection for anti‐EGFR‐directed therapies. Cancer 2006. © 2006 American Cancer Society.

show abstract

Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder

Cited by 179 publications

References 32 publications

Frequent and heterogenous expression of cyclin-dependent kinase inhibitor WAF1/p21 protein and mRNA in urothelial carcinoma

Frequent and heterogenous expression of cyclin-dependent kinase inhibitor WAF1/p21 protein and mRNA in urothelial carcinoma

Immunohistochemical Expression of CK20, p53, and Ki-67 as Objective Markers of Urothelial Dysplasia

Serum epidermal growth factor receptor/HER‐2 predicts poor survival in patients with metastatic breast cancer

Contact Info

Product

Resources

About